佳緣科技(301117.SZ):再次通過2022年度四川省“專精特新”中小企業認定
格隆匯11月10日丨佳緣科技(301117.SZ)公佈,根據四川省經濟和信息化廳發佈的《關於公佈2022年度四川省“專精特新”中小企業名單及通過複核企業名單的通知》(川經信企業函[2022]821號),公司再次通過2022年度四川省“專精特新”中小企業認定,有效期三年。
此次“專精特新”中小企業的認定,是對公司在細分市場專業化、企業管理精細化、產品或服務特色化、科技成果新穎化等多方面的肯定,有利於提高公司品牌的知名度和行業影響力,進一步增強公司的市場競爭力,對公司的長遠發展具有積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.